Public markets showed renewed appetite for biotech this week as Eikon Therapeutics priced an upsized IPO that will generate approximately $381 million and several other drugmakers completed offerings that together approached $1 billion in proceeds. The wave included listings and filings from companies focused on oncology, fibrosis, and immunology. Eikon said it intends to deploy IPO proceeds to advance its clinical‑stage programs, including TLR7/8 co‑agonists and selective PARP inhibitors. Market observers flagged the cluster of listings as a potential turning point for biotech financing after several muted years of public exits. The flurry of activity could ease private financing pressures and reset valuations for clinical‑stage assets, but aftermarket reactions will determine whether this cohort sustains momentum. Biotech CFOs and deal teams will weigh the timing and structure of future offerings against this fresh data point for institutional demand.